TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...
SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.
While there was no change in disability-free survival, the results should impact guidelines, says François Mach.
Starting evolocumab in the cath lab before PCI did not, however, result in better clinical outcomes in the first year.
The CMR GUIDE trial didn’t meet its primary endpoint but did point to possible positives, especially in younger patients.
Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...
The US Food and Drug Administration has granted an expanded indication to tirzepatide (Mounjaro) for reducing major adverse ...
Because of the low number of events in the trial, the findings are thought-provoking but not definitive, one expert says.
At TCT 2025, Jeff Popma interviews Sahar Samimi and Sachin Goel about the simultaneous presentation and publication of their ...
The agency says the company has reported 37 serious injuries and three deaths related to the issue as of August 17.
Compared with standard treatment, an abbreviated regimen was associated with more relapses but didn’t compromise safety.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results